Full Length Research Paper
References
|
Alvarez OA, Zimmerman G (2000). Pegaspargase-induced pancreatitis. Med. Pediatr. Oncol. 34:200-205. Crossref |
||||
|
Aslanian AM, Fletcher BS, Kilberg MS (2001). asparagine synthetase expression alone is sufficient to in- duce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochemical. J. 357:321-328. Crossref |
||||
|
Aslanian AM, Kilberg MS (2001). Multiple Adaptive Mechanisms Affect Asparagine Synthetase Substrate Availability in Asparaginase-Resistant MOLT-4 Leukaemia Cells. Biochemical J. 358:59-67. Crossref |
||||
|
Avramis VI, Panosyan EH (2005). Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin. Pharmacokinet. 44: 367-393. Crossref |
||||
|
Baran ET, Ozer N, Hasirci V. (2002). In vivo half-life of nanoencapsulated L-asparaginase.J. Mater. Sci. Mater. Med. 13(12):1113-21. Crossref |
||||
|
Barry E, DeAngelo DJ, Neuberg D (2007). Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J. Clin. Oncol. 25:813-819. Crossref |
||||
|
Bommarius AS, Broering JM, Chaparro-Riggers JF, Polizzi KM (2006) High-throughput screening for enhanced protein stability. Curr. Opin. Biotechnol. 17:606-610. Crossref |
||||
|
Bradford M (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72:248-254. Crossref |
||||
|
Burnham NL (1994). Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51:210-218. Pubmed |
||||
|
Cantor RJ, Panayiotou V, Agnello G, Georgiou G, Everett MS (2011). Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in Cancer. Methods in Enzymol. 502: 291-319. Crossref |
||||
|
Capizzi RL (1993). Asparaginase revisited. Leuk Lymphoma, 10(Suppl):147-50. Crossref |
||||
| Chabner BA, Loo TL (1996). Enzyme therapy: L-asparaginase. In: Chabner BA, Longo DL (eds). Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven, Philadelphia. 485-492. | ||||
| Christian D, Johannes H,Heinrichröhm K. (2000). Protein Science. (9): 2009-2017. | ||||
|
Cornelis P (2000). Expressing genes in differentEscherichia coli compartments.Curr. Opin. Biotechnol. (11): 450-454. Crossref |
||||
|
Daniel RM, Cowan DA, Morgan HW, Curran MP (1982). A correlation between protein thermostability and resistance to proteolysis. Biochem. J. 207(3):641-4. Pubmed |
||||
| David K, David G (1972). L-asparaginase production by the rumen anaerobe Vibrio succinogenes. J. Appl. Microbial. 27:206-209. | ||||
|
Duval M, Suciu S, Ferster A (2002). Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 99:2734-2739. Crossref |
||||
|
Fernandes AI, Gregoriadis G (1997). Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochim. Biophys. Acta. 1341:26-34. Crossref |
||||
| Garfin DE, (1970). One-dimensional electrophoresis. In: Methods in enzymology, Deutscher, M.P. (ed.). 182:425-441. Academic press, New York. | ||||
| Giver L, Gershenson A, Freskgard PO, Arnold FH (1998). Directed evolution of a thermostable esterase. Biochemistry. 95: 12809-12813. | ||||
| Godfrin, Yann and Bertrand, Yves (2006): L-asparaginase Introduced into Erythrocytes for the Treatment of Leukaemia (ALL) 1 (1) :10-13. | ||||
|
Goldberg DM (1992). Enzymes as agents for the treatment of disease. Clin. Chim. Acta. 206:45-76. Crossref |
||||
|
Gulati R, Saxena RK, Gupta R (1997). A rapid plate assay for screening L-asparaginase producing micro-organisms. Lett. Appl. Microbiol. 24 (1):23-6. Crossref |
||||
|
Hao J, Berry A (2004). A thermostable variant of fructose bisphosphatealdolase constructed by directed evolution also shows increased stability in organic solvents. Protein Eng. Des. Sel. 17: 689-697. Crossref |
||||
|
Harms E, Wehner A, Jennings MP, Pugh KJ, Beacham IR, Rohm KH (1991). Construction of expression systems for Escherichia coli asparaginase II and two-step purification of the recombinant enzyme from periplasmic extracts, Protein Express. Purif. :2:144-150. Crossref |
||||
|
Horowitz B, Old LJ, Boyse EA, Stockert E (1968). Asparagine synthetaseactivity of mouse leukemias. Science. 160: 533-535. Crossref |
||||
|
Imada A, Igarasi S, Nakahama K, Isona M (1973). Asparaginase and glutaminase activities of microorganisms. J. General Microbiol. 76: 85-99. Crossref |
||||
|
Imanaka T, Nakae M, Ohta T, Takagi M (1992). Design of temperature-sensitive penicillinase repressors by replacement of pro in predicted - turn structures. J. Bacteriol. 174(4):1423-5. Pubmed |
||||
|
Imanaka T, Shibazaki M, Takagi M (1986). A new way of enhancing the thermostability of proteases. Nature. 324:695-7. Crossref |
||||
|
Jonasson P,Liljeqvist S, Nygren PA, Stahl S (2002). Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli. Biotechnol. Appl. Biochem. (35):91-105. Crossref |
||||
| Joseph R (1976). Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7Z. J. Biol. Chem. 251:2119-2123. | ||||
|
Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB (2009). Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr. Blood Cancer. 53:162-167. Crossref |
||||
|
Keating MJ, Holmes R, Lerner S, Ho DH (1993). l-Asparaginase and PEG asparaginase - past, present, and future. Leuk. Lymphoma. 10: 153-157. Crossref |
||||
|
Kotzia GA, Labrou NE (2005). Cloning, expression and characterization of Erwiniacarotovora l-asparaginase. J. Biotechnol. 119: 309-323. Crossref |
||||
|
Kotzia GA, Labrou NE (2007). l-Asparaginase from Erwiniachrysanthemi 3937: cloning, expression and characterization. J. Biotechnol. 127:657-669. Crossref |
||||
|
Kotzia, GA, Labrou NE (2009). Engineering thermal stability of L-asparaginase by in vitro directed evolution.FEBS. J. 276(6):1750-61. Crossref |
||||
|
Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-685. Crossref |
||||
|
Larson RA, Fretzin MH, Dodge RK, Schiffer CA (1998). Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 12: 660-665. Crossref |
||||
| Making H, lnada Y (1975). Immunochemical properties of asparaginase modified by chemical substitution. Immunochemistry. 12:I83. | ||||
|
Makrides SC (1996). Strategies for achieving high-level expression of genes in Escherichia coli.Microbiol. Rev. (60):512-538. Pubmed |
||||
|
Muller HJ, Boos J (1998). Use of L-asparaginase in childhood ALL. Crit. Rev. Oncol. Hematol. 28:97-113 Crossref |
||||
|
Nowak-Göttl U, Ahlke E, Fleischhack G, (2003). Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 101:2529-2533. Crossref |
||||
|
Oh KH, Nam SH, Kim HS (2002). Improvement of oxidative and thermostability of N-carbamyl-d-amino acid amidohydrolase by directed evolution. Protein Eng. 15:689-695. Crossref |
||||
|
Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI (2004). Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer. Res. 24:1121-1125. Pubmed |
||||
|
Pavelic KS, Sedic M, Bosnjak H, Spaventi S, Pavelic K (2011). Metastasis: new perspectives on an old problem. Mol Cancer. 10:22. Crossref |
||||
|
Pieters R, Stephen P, Hunger,; Joachim Boos,; Carmelo Rizzari; Lewis Silverman; Andre Baruchel; Nicola Goekbuget; Martin Schrappe; and Ching-Hon Pui (2011).L-Asparaginase Treatment in Acute Lymphoblastic Leukemia A Focus on Erwinia Asparaginase. Cancer. 238-249. Crossref |
||||
|
Prager MD, Bachynsky N (1968). Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase. Arch. Biochem. Biophys. 127: 645-654. Crossref |
||||
| Sambrook J, Fritsch EF, Maniatis T (1989). Molecular cloning: A laboratory manual. 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press | ||||
|
Sanden AM, Prytz I, Tubulekas I, Forberg C, Le H, Hektor A, Neubauer P, Pragai Z, Harwood C, Ward A, Picon A, De Mattos JT, Postma P, Farewell A, Nystrom T, Reeh S, Pedersen S, Larsson G (2003). Limiting factors in Escherichia coli fedbatch production of recombinant proteins. Biotechnol. Bioeng. 81:158-166. Crossref |
||||
|
Shokri A, Sanden AM, Larsson G (2002). Growth rate-dependent changes in Escherichia coli membrane structure and protein leakage. Appl. Microbiol. Biotechnol. 58:386-392. Crossref |
||||
|
Stecher AL, de Deus PM, Polikarpov I, Abrahao-Neto J. (1999). Stability of L-asparaginase: an enzyme used in leukemia treatment. Pharm. Acta. Helv. 74:1-9 Crossref |
||||
|
Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH (1985). Human Acute Leukemia Cell Line with the t (4:11) Chromosomal Rearrangement Exhibits B Lineage and Monocytic Characteristics. Blood. 65(1):21-31. Pubmed |
||||
|
Story MD, Voehringer DW, Stephens LC, Meyn RE (1993). L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother. Pharmacol. 32(2):129-33. Crossref |
||||
|
Towbin H, Staehelin T, Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad.Sci. USA.76:4350-4354 Crossref |
||||
|
Ueno T, Ohtawa K, Mitsui K, Kodera Y, Hiroto M, Matsushima A, Inada Y, Nishimura H (1997). Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia. 11(11):1858-61. Crossref |
||||
|
Veronese FM, Pasut G (2005). PEGylation, successful approach to drug delivery. Drug Discov. Today. 10: 1451-1458. Crossref |
||||
|
Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Wurthwein G, Janka-Schaub G, Boos J (2006). Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU / m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr. Blood Cancer 46:18-25. Crossref |
||||
|
Woo MH, Hak LJ, Storm MC (2000).Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18:1525-1532. Pubmed |
||||
|
Wriston JC Jr. (1985). Asparaginase. Meth. Enzymol. 113: 608-618. Crossref |
||||
|
Yu-Qing Z, Mei-Lin T, Wei-De S, Yu-Zhen Z, Yue D, Yan M (2004). Immobilization of L-asparaginase on the microparticles of the natural silk sericin protein and its characters. Biomaterials. 25:3751-3759. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
